• 00Days
  • 00Hours
  • 00Minutes
  • 00Seconds

Overview

Over the course of the last decade, we have witnessed the emergence of therapeutic antibodies, and more specifically, monoclonal antibodies (mAbs) as one of the fastest-growing classes of pharmaceutical drugs.

It (along with recombinant proteins) has powered the growth of the biopharmaceuticals industry, and it is expected to grow to a market value of USD 496.71 billion by 2026, with a CAGR of 7.32% over the forecast period 2021-2026. Notably, the global therapeutic monoclonal antibody market is expected to be valued at $300 billion by 2025.

Some significant trends that appear to be developing across the industry landscape include greater development of bispecific antibodies, antibody-drug conjugates, and companion diagnostics, which should help to identify the most appropriate patient populations for treatment. Additionally, new markets are expected to open up in growing economies. How companies respond to these scientific and business challenges will define their future as producers of innovative mAbs and Fc fusion proteins of the future.

Thus, interest in therapeutic monoclonal antibodies has piqued industry onlookers. This can perhaps be attributed to the incredible specificity made possible by mAbs, epitomising precision medicine via an incredibly flexible platform boasting numerous advantages. The greatest challenge before us now is to understand the underlying biology in order to ensure the efficacy of medical treatments, and usher in an entirely new generation of therapeutic agents built on the premise of molecular-targeting medicine.

Through the lens of a new knowledge platform, christened Futurescope, Bluetech Media aims to explore the Pharma Possibilities of Therapeutic Monoclonal Antibodies. By shining a spotlight on this game-changing development, we seek to better understand its use cases, implications, and future horizons.

Guest Speakers

Anurag Tandon

Vice President – METAI & APAC
(Excl China & Japan) region
Beckman Coulter Life Sciences

Narendra Chirmule

Co-foundern & CEO
Symphony Tech Biologics

Dr. Ratnesh Jain

Head & Course Coordinator,
Bioprocess Technology, ICT, Mumbai

Dr. Niti M. Jetly

Application specialist,
Molecular Devices

Who should attend

Designation

CXO’s | VP’s | Sr.  Manager | Manager

Department

QA /QC

R & D

Regulatory

Why Attend

This market space is dynamic, and we expect it to evolve rapidly and constantly. As such, the central questions that emerge will change over time with the advent of new developments.

With this context, we view this knowledge platform as essential for the advancement of the industry, and the expansion of knowledge bases at an individual level.

By undertaking periodic endeavours to decode the present & illuminate an ever-evolving future, we believe that delegates will be in pole position to imbibe insights across four key sources vital to advancing the cause of industry & society, namely:

  • Insights from august industry veterans.
  • Presentations by industry experts on the latest advancements.
  • Cutting-edge case studies and learnings from across the globe.
  • Analysing emerging opportunities and future implications.

Gaining an in-depth knowledge of these myriad facets from across the industry landscape will give delegates an upper hand to outperform peers & innovate relentlessly.

AGENDA

11:20

REGISTRATION

11:30

WELCOME REMARK BY BLUETECH MEDIA

11:35

KEY NOTE ADDRESS FROM ANURAG TANDON VP – METAI & APAC (Excl China & Japan) region,
Beckman Coulter Life Sciences

11:45

INFLECTION POINT : EXPLORING THE FUTURE OF MONOCLONAL THERAPY

12:05

ANALYTICAL CHARACTERISATION FOR MAB DEVELOPMENT

12:25

FUTURE OF THERAPEUTIC MONOCLONAL ANTIBODIES

12:45

Q&A

01:05

Closing Remarks by BlueTech Media

Copyright @ 2021 bluetech-media.com, All Rights Reserved,
Design & Develope by webtech.ooo